Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma
David S Siegel1, Ravi Vij, Andrzej J Jakubowiak
1Chief Myeloma Division, John Theuer Cancer Center, Hackensack, New Jersey, USA.
Abstract:
Multiple myeloma is a major hematologic malignancy, with an incidence of over 20,000 new diagnoses in the United States each year. Historically, a lack of effective therapies led to a poor patient prognosis. However, the introduction of new agents over the past decade has improved the treatment landscape for these patients, resulting in improved responses and prolonged progression-free and overall survival. Unfortunately, though, nearly all multiple myeloma patients go on to experience relapsed disease. The definition of this progression has also evolved with a growing understanding of the biology of multiple myeloma as well how the disease responds to these newer agents. While refractory multiple myeloma is considered to be a disease that does not respond to a particular therapy, the new definition of relapsed and refractory multiple myeloma includes patients who show disease progression within 60 days of discontinuing therapy. These new definitions are an important consideration when interpreting both previously reported and ongoing clinical trial data. Another major issue in the management of relapsed and refractory multiple myeloma is how to treat patients after they no longer respond to thalidomide, lenalidomide, and bortezomib. Regarding this issue, a number of novel agents are now in clinical trial development; many of them show indications of significant activity, even in heavily pretreated patients. Thus, the introduction of these newer agents has the potential to again make a major impact on multiple myeloma patient outcomes.
Insights
New therapies are improving outcomes for multiple myeloma patients, but relapsed disease remains common. Novel agents show promise for treating relapsed and refractory multiple myeloma, even in pretreated patients.
Area of Science:
- Hematologic Malignancies
- Oncology
- Clinical Therapeutics
Background:
- Multiple myeloma is a significant blood cancer with over 20,000 US diagnoses annually.
- Historically, limited effective treatments led to poor prognoses for multiple myeloma patients.
- Recent advancements in therapeutic agents have improved patient responses and survival rates.
Purpose of the Study:
- To discuss the evolving definitions and management challenges of relapsed and refractory multiple myeloma.
- To highlight the impact of novel agents in the treatment landscape of multiple myeloma.
- To underscore the potential of new therapies for improving outcomes in heavily pretreated patients.
Main Methods:
- Review of current literature on multiple myeloma treatment and management.
- Analysis of evolving definitions for relapsed and refractory disease.
- Evaluation of emerging novel agents in clinical trials for multiple myeloma.
Main Results:
- The introduction of new agents has significantly improved treatment outcomes and survival for multiple myeloma patients.
- Nearly all patients eventually experience relapsed disease, necessitating updated management strategies.
- New definitions of relapsed and refractory multiple myeloma impact clinical trial data interpretation.
Conclusions:
- Novel agents in development show significant activity, offering new hope for relapsed and refractory multiple myeloma.
- These emerging therapies have the potential to substantially improve outcomes for patients with advanced multiple myeloma.
- Understanding evolving disease definitions is crucial for interpreting clinical trial data and guiding treatment decisions.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Therapeutic Drug Monitoring: Affecting Factors
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...